KR20090066289A - 알코올 유발성 뇌 질환의 치료, 예방 및 역행 - Google Patents

알코올 유발성 뇌 질환의 치료, 예방 및 역행 Download PDF

Info

Publication number
KR20090066289A
KR20090066289A KR1020097007172A KR20097007172A KR20090066289A KR 20090066289 A KR20090066289 A KR 20090066289A KR 1020097007172 A KR1020097007172 A KR 1020097007172A KR 20097007172 A KR20097007172 A KR 20097007172A KR 20090066289 A KR20090066289 A KR 20090066289A
Authority
KR
South Korea
Prior art keywords
igf
insulin
ethanol
brain
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097007172A
Other languages
English (en)
Korean (ko)
Inventor
라 몬트 수잔 마리 드
잭 레이먼드 완즈
Original Assignee
로드아일랜드하스피틀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로드아일랜드하스피틀 filed Critical 로드아일랜드하스피틀
Publication of KR20090066289A publication Critical patent/KR20090066289A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Environmental Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020097007172A 2006-09-08 2007-09-10 알코올 유발성 뇌 질환의 치료, 예방 및 역행 Ceased KR20090066289A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84298806P 2006-09-08 2006-09-08
US60/842,988 2006-09-08

Publications (1)

Publication Number Publication Date
KR20090066289A true KR20090066289A (ko) 2009-06-23

Family

ID=39157889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007172A Ceased KR20090066289A (ko) 2006-09-08 2007-09-10 알코올 유발성 뇌 질환의 치료, 예방 및 역행

Country Status (7)

Country Link
US (1) US9308198B2 (https=)
EP (1) EP2061442B1 (https=)
JP (1) JP2010502719A (https=)
KR (1) KR20090066289A (https=)
AU (1) AU2007292883B2 (https=)
CA (1) CA2663121C (https=)
WO (1) WO2008030604A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
JP2013194007A (ja) * 2012-03-21 2013-09-30 Cci Corp 抗酸化ストレス剤およびその用途
CA2878402A1 (en) * 2012-07-06 2014-01-09 Omeros Corporation Andrographis paniculata compositions and methods for treatment of addictions
US8865761B1 (en) 2012-08-07 2014-10-21 The University Of Notre Dame Du Lac Regulation of cholesterol homeostasis

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5223242A (en) 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
AU5811298A (en) 1996-12-31 1998-07-31 Salk Institute For Biological Studies, The Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6060515A (en) 1997-01-24 2000-05-09 The Regents Of The University Of California Treatment of skin conditions by use of PPARα activators
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
BR9814087A (pt) 1997-10-17 2000-10-03 Aventis Pharm Prod Inc Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
GB9824614D0 (en) 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
US6713514B1 (en) 1999-04-19 2004-03-30 Lexicon Pharmaceuticals, Inc. PPAR-γ agonists as agents for the treatment of type II diabetes
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
ES2277842T3 (es) 1999-06-18 2007-08-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y de ariloxazolidindiona.
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
US6949259B1 (en) 1999-11-11 2005-09-27 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
US6462046B2 (en) 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
WO2001087860A2 (en) 2000-05-12 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
US6908908B2 (en) 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
ES2288957T3 (es) 2000-05-12 2008-02-01 Ortho-Mcneil Pharmaceutical, Inc. 4h-benzo(1.4)oxazin-3-ina biologicamente activas.
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
CA2417005A1 (en) 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
AU2001292874B2 (en) 2000-09-27 2006-06-15 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
PL366068A1 (en) 2000-10-10 2005-01-24 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法
JP4350946B2 (ja) 2000-10-31 2009-10-28 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7091225B2 (en) 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AU2002251978B2 (en) 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
EP1360172A1 (en) 2001-02-15 2003-11-12 Pfizer Products Inc. Ppar agonists
ITRM20010136A1 (it) 2001-03-16 2002-09-16 Sigma Tau Ind Farmaceuti Composti utili per il trattamento di patologie che rispondono all'attivazione del recettore ppar-gamma.
US6548538B2 (en) 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
JP2002368028A (ja) 2001-06-13 2002-12-20 Nec Corp 半導体パッケージ及びその製造方法
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
JP4179494B2 (ja) 2001-10-23 2008-11-12 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US6673823B2 (en) 2002-06-04 2004-01-06 Cedars-Sinai Medical Center Use of peroxisome proliferator activated receptor (PPAR)-γ ligands as a treatment for pituitary tumors and associated conditions, such as Cushing's syndrome
CA2499380A1 (en) 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
EP1682507A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
ATE557013T1 (de) 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1742923B1 (en) 2004-04-28 2009-05-27 F.Hoffmann-La Roche Ag Pyrazole phenyl derivatives as ppar activators
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
EP3788877B1 (en) 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions

Also Published As

Publication number Publication date
WO2008030604A3 (en) 2008-06-26
JP2010502719A (ja) 2010-01-28
AU2007292883B2 (en) 2013-09-05
WO2008030604A2 (en) 2008-03-13
EP2061442A4 (en) 2009-11-11
EP2061442B1 (en) 2016-08-31
AU2007292883A1 (en) 2008-03-13
US20100055037A1 (en) 2010-03-04
US9308198B2 (en) 2016-04-12
CA2663121C (en) 2016-01-19
CA2663121A1 (en) 2008-03-13
EP2061442A2 (en) 2009-05-27

Similar Documents

Publication Publication Date Title
EP2001503B1 (en) Diagnosis and treatment of alzheimer's disease
Torres et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats
US20140011761A1 (en) Modulating Endoplasmic Reticulum Stress in the Treatment of Tuberous Sclerosis
EP1817050B1 (en) Diagnosis and treatment of alzheimer's disease
KR20090066289A (ko) 알코올 유발성 뇌 질환의 치료, 예방 및 역행
Kim et al. TAZ stimulates exercise‐induced muscle satellite cell activation via Pard3–p38 MAPK–TAZ signalling axis
WO2013020372A1 (zh) 防治胰岛素抵抗和糖尿病的方法和试剂
KR101922515B1 (ko) 알코올 유발성 간 질환의 치료, 예방 및 역행
Sari et al. Activity-dependent neurotrophic factor-derived peptide prevents alcohol-induced apoptosis, in part, through Bcl2 and c-Jun N-terminal kinase signaling pathways in fetal brain of C57BL/6 mouse
Jo et al. Synergistic effects of C–C chemokine receptor 2 inhibitor and transforming growth factor-β type I receptor kinase inhibitor combination in metabolic dysfunction-associated steatohepatitis
Lv et al. Miltefosine as a PPM1A activator improves AD-like pathology in mice by alleviating tauopathy via microglia/neurons crosstalk
JP7303407B2 (ja) 腫瘍の診断および治療におけるＡｋｔ２の使用
Hirai et al. The role of insulin growth factor on atherosclerosis and endothelial function: the effect on hyperlipidemia and aging
US20090305225A1 (en) Inhibition of Creatine Uptake to Promote Weight Loss
JP2005261203A (ja) 骨格筋の組成及び量を改善する薬剤をスクリーニングする方法
KR20240052222A (ko) 건선의 중증도 진단용 바이오마커
Nakamura et al. Su1250 Glucagon-Like Peptide-1 Does Not Enhance Inflammatory Responses in Pancreatic Stellate Cells, but Induces Cell Proliferation via ERK Pathway
KR20200124018A (ko) Pdk2 억제제를 유효성분으로 함유하는 식욕 조절용 조성물
Mansour et al. Leptin inhibits apoptosis in thymus through a JAK-2 independent, IRS-1/PI-3 kinase dependent pathway

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090407

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120904

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131031

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140926

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131031

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20141229

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140926

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20160829

Appeal identifier: 2014101008105

Request date: 20141229

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20150112

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20141229

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20140430

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20120904

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150223

Patent event code: PE09021S01D

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20151130

J301 Trial decision

Free format text: TRIAL NUMBER: 2014101008105; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141229

Effective date: 20160829

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20160829

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20141229

Decision date: 20160829

Appeal identifier: 2014101008105